HEADER HORMONE RECEPTOR 25-AUG-10 3OKI TITLE CRYSTAL STRUCTURE OF HUMAN FXR IN COMPLEX WITH (2S)-2-[2-(4- TITLE 2 CHLOROPHENYL)-1H-BENZIMIDAZOL-1-YL]-N,2-DICYCLOHEXYLETHANAMIDE COMPND MOL_ID: 1; COMPND 2 MOLECULE: BILE ACID RECEPTOR; COMPND 3 CHAIN: A, C; COMPND 4 FRAGMENT: UNP RESIDUES 258-486; COMPND 5 SYNONYM: FXR, FARNESOID X-ACTIVATED RECEPTOR, FARNESOL RECEPTOR HRR- COMPND 6 1, NUCLEAR RECEPTOR SUBFAMILY 1 GROUP H MEMBER 4, RETINOID X COMPND 7 RECEPTOR-INTERACTING PROTEIN 14, RXR-INTERACTING PROTEIN 14; COMPND 8 ENGINEERED: YES; COMPND 9 MUTATION: YES; COMPND 10 MOL_ID: 2; COMPND 11 MOLECULE: PEPTIDE OF NUCLEAR RECEPTOR COACTIVATOR 1; COMPND 12 CHAIN: B, D; COMPND 13 FRAGMENT: UNP RESIDUES 744-757; COMPND 14 SYNONYM: NCOA-1, CLASS E BASIC HELIX-LOOP-HELIX PROTEIN 74, BHLHE74, COMPND 15 PROTEIN HIN-2, RIP160, RENAL CARCINOMA ANTIGEN NY-REN-52, STEROID COMPND 16 RECEPTOR COACTIVATOR 1, SRC-1; COMPND 17 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: NR1H4, HCG_20893; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 8 EXPRESSION_SYSTEM_STRAIN: BL21(DE3); SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 10 EXPRESSION_SYSTEM_PLASMID: PET28A; SOURCE 11 MOL_ID: 2; SOURCE 12 SYNTHETIC: YES; SOURCE 13 OTHER_DETAILS: THIS SEQUENCE OCCURS NATURALLY IN HUMANS KEYWDS NUCLEAR RECEPTOR, CHOLESTEROL, BILE ACID, DNA-BINDING, NUCLEUS, KEYWDS 2 RECEPTOR, TRANSCRIPTION, LIGAND BINDING DOMAIN TRANSCRIPTION KEYWDS 3 REGULATION, COACTIVATOR, FXR ALTERNATIVE SPLICING, HORMONE RECEPTOR EXPDTA X-RAY DIFFRACTION AUTHOR M.G.RUDOLPH REVDAT 3 03-APR-24 3OKI 1 REMARK REVDAT 2 20-MAR-24 3OKI 1 REMARK SEQADV REVDAT 1 29-DEC-10 3OKI 0 JRNL AUTH H.G.F.RICHTER,G.M.BENSON,D.BLUM,E.CHAPUT,S.FENG,C.GARDES, JRNL AUTH 2 U.GRETHER,P.HARTMAN,B.KUHN,R.E.MARTIN,J.-M.PLANCHER, JRNL AUTH 3 M.G.RUDOLPH,F.SCHULER,S.TAYLOR,K.H.BLEICHER JRNL TITL DISCOVERY OF NOVEL AND ORALLY ACTIVE FXR AGONISTS FOR THE JRNL TITL 2 POTENTIAL TREATMENT OF DYSLIPIDEMIA & DIABETES JRNL REF BIOORG.MED.CHEM.LETT. V. 21 191 2010 JRNL REFN ISSN 0960-894X JRNL PMID 21134747 JRNL DOI 10.1016/J.BMCL.2010.11.039 REMARK 2 REMARK 2 RESOLUTION. 2.00 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : PHENIX (PHENIX.REFINE: 1.6.4_486) REMARK 3 AUTHORS : PAUL ADAMS,PAVEL AFONINE,VINCENT CHEN,IAN REMARK 3 : DAVIS,KRESHNA GOPAL,RALF GROSSE-KUNSTLEVE, REMARK 3 : LI-WEI HUNG,ROBERT IMMORMINO,TOM IOERGER, REMARK 3 : AIRLIE MCCOY,ERIK MCKEE,NIGEL MORIARTY, REMARK 3 : REETAL PAI,RANDY READ,JANE RICHARDSON, REMARK 3 : DAVID RICHARDSON,TOD ROMO,JIM SACCHETTINI, REMARK 3 : NICHOLAS SAUTER,JACOB SMITH,LAURENT REMARK 3 : STORONI,TOM TERWILLIGER,PETER ZWART REMARK 3 REMARK 3 REFINEMENT TARGET : ML REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.00 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 31.27 REMARK 3 MIN(FOBS/SIGMA_FOBS) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 77.5 REMARK 3 NUMBER OF REFLECTIONS : 30807 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 R VALUE (WORKING + TEST SET) : 0.248 REMARK 3 R VALUE (WORKING SET) : 0.246 REMARK 3 FREE R VALUE : 0.280 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 4.810 REMARK 3 FREE R VALUE TEST SET COUNT : 1481 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (IN BINS). REMARK 3 BIN RESOLUTION RANGE COMPL. NWORK NFREE RWORK RFREE REMARK 3 1 31.2769 - 4.4441 0.95 3421 189 0.2104 0.2168 REMARK 3 2 4.4441 - 3.5290 0.64 2200 128 0.2139 0.2625 REMARK 3 3 3.5290 - 3.0833 0.99 3433 158 0.2620 0.3208 REMARK 3 4 3.0833 - 2.8016 1.00 3443 169 0.2703 0.3190 REMARK 3 5 2.8016 - 2.6009 0.99 3372 185 0.2782 0.3328 REMARK 3 6 2.6009 - 2.4476 0.98 3351 160 0.2895 0.3538 REMARK 3 7 2.4476 - 2.3251 0.96 3215 175 0.3070 0.3729 REMARK 3 8 2.3251 - 2.2239 0.21 643 22 0.3419 0.2631 REMARK 3 9 2.2239 - 2.1383 0.68 1933 89 0.3397 0.4097 REMARK 3 10 2.1383 - 2.0645 0.70 2372 107 0.3335 0.4069 REMARK 3 11 2.0645 - 2.0000 0.57 1943 99 0.3875 0.4171 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : FLAT BULK SOLVENT MODEL REMARK 3 SOLVENT RADIUS : 1.11 REMARK 3 SHRINKAGE RADIUS : 0.90 REMARK 3 K_SOL : 0.40 REMARK 3 B_SOL : 58.91 REMARK 3 REMARK 3 ERROR ESTIMATES. REMARK 3 COORDINATE ERROR (MAXIMUM-LIKELIHOOD BASED) : 0.280 REMARK 3 PHASE ERROR (DEGREES, MAXIMUM-LIKELIHOOD BASED) : 37.220 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 47.79 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 57.61 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -3.63750 REMARK 3 B22 (A**2) : 5.85330 REMARK 3 B33 (A**2) : -2.21570 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 TWINNING INFORMATION. REMARK 3 FRACTION: NULL REMARK 3 OPERATOR: NULL REMARK 3 REMARK 3 DEVIATIONS FROM IDEAL VALUES. REMARK 3 RMSD COUNT REMARK 3 BOND : 0.002 4114 REMARK 3 ANGLE : 0.513 5556 REMARK 3 CHIRALITY : 0.037 620 REMARK 3 PLANARITY : 0.002 706 REMARK 3 DIHEDRAL : 14.965 1552 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 NCS DETAILS REMARK 3 NUMBER OF NCS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 3OKI COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBJ ON 07-SEP-10. REMARK 100 THE DEPOSITION ID IS D_1000061230. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 27-NOV-06 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 6.5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : SLS REMARK 200 BEAMLINE : X06SA REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.9721 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : MARMOSAIC 225 MM CCD REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS REMARK 200 DATA SCALING SOFTWARE : SADABS REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 30936 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.000 REMARK 200 RESOLUTION RANGE LOW (A) : 36.030 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 79.9 REMARK 200 DATA REDUNDANCY : 4.200 REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 13.0600 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.02 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.12 REMARK 200 COMPLETENESS FOR SHELL (%) : 73.5 REMARK 200 DATA REDUNDANCY IN SHELL : 3.00 REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER REMARK 200 STARTING MODEL: INHOUSE REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 51.04 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.51 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 0.1M BIS-TRIS PH 6.5, 28% PEG 2000, REMARK 280 VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 298K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: C 2 2 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,-Y,Z+1/2 REMARK 290 3555 -X,Y,-Z+1/2 REMARK 290 4555 X,-Y,-Z REMARK 290 5555 X+1/2,Y+1/2,Z REMARK 290 6555 -X+1/2,-Y+1/2,Z+1/2 REMARK 290 7555 -X+1/2,Y+1/2,-Z+1/2 REMARK 290 8555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 95.12000 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 95.12000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 5 1.000000 0.000000 0.000000 36.10750 REMARK 290 SMTRY2 5 0.000000 1.000000 0.000000 42.26400 REMARK 290 SMTRY3 5 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 6 -1.000000 0.000000 0.000000 36.10750 REMARK 290 SMTRY2 6 0.000000 -1.000000 0.000000 42.26400 REMARK 290 SMTRY3 6 0.000000 0.000000 1.000000 95.12000 REMARK 290 SMTRY1 7 -1.000000 0.000000 0.000000 36.10750 REMARK 290 SMTRY2 7 0.000000 1.000000 0.000000 42.26400 REMARK 290 SMTRY3 7 0.000000 0.000000 -1.000000 95.12000 REMARK 290 SMTRY1 8 1.000000 0.000000 0.000000 36.10750 REMARK 290 SMTRY2 8 0.000000 -1.000000 0.000000 42.26400 REMARK 290 SMTRY3 8 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 1120 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 12530 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -6.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 1140 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 12320 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -8.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: C, D REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A 244 REMARK 465 SER A 245 REMARK 465 HIS A 246 REMARK 465 LYS B 744 REMARK 465 GLU B 757 REMARK 465 GLY C 244 REMARK 465 SER C 245 REMARK 465 HIS C 246 REMARK 465 LYS D 744 REMARK 465 ASP D 745 REMARK 465 ASP D 756 REMARK 465 GLU D 757 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 PRO A 345 150.99 -49.86 REMARK 500 LEU A 395 48.21 -89.09 REMARK 500 ASP A 398 37.81 -79.40 REMARK 500 TYR A 401 -3.65 70.58 REMARK 500 PRO A 431 27.40 -75.77 REMARK 500 ASP A 474 64.51 -110.27 REMARK 500 TYR C 401 -2.68 76.45 REMARK 500 ASP D 754 45.93 -106.56 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE OKI A 2 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE OKI C 1 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 3OKH RELATED DB: PDB REMARK 900 RELATED ID: 3OLF RELATED DB: PDB REMARK 900 RELATED ID: 3OMK RELATED DB: PDB REMARK 900 RELATED ID: 3OMM RELATED DB: PDB REMARK 900 RELATED ID: 3OOF RELATED DB: PDB REMARK 900 RELATED ID: 3OOK RELATED DB: PDB DBREF 3OKI A 248 476 UNP Q96RI1 NR1H4_HUMAN 258 486 DBREF 3OKI B 744 757 UNP Q15788 NCOA1_HUMAN 744 757 DBREF 3OKI C 248 476 UNP Q96RI1 NR1H4_HUMAN 258 486 DBREF 3OKI D 744 757 UNP Q15788 NCOA1_HUMAN 744 757 SEQADV 3OKI GLY A 244 UNP Q96RI1 EXPRESSION TAG SEQADV 3OKI SER A 245 UNP Q96RI1 EXPRESSION TAG SEQADV 3OKI HIS A 246 UNP Q96RI1 EXPRESSION TAG SEQADV 3OKI MET A 247 UNP Q96RI1 EXPRESSION TAG SEQADV 3OKI ALA A 281 UNP Q96RI1 GLU 291 ENGINEERED MUTATION SEQADV 3OKI ALA A 354 UNP Q96RI1 GLU 364 ENGINEERED MUTATION SEQADV 3OKI GLY C 244 UNP Q96RI1 EXPRESSION TAG SEQADV 3OKI SER C 245 UNP Q96RI1 EXPRESSION TAG SEQADV 3OKI HIS C 246 UNP Q96RI1 EXPRESSION TAG SEQADV 3OKI MET C 247 UNP Q96RI1 EXPRESSION TAG SEQADV 3OKI ALA C 281 UNP Q96RI1 GLU 291 ENGINEERED MUTATION SEQADV 3OKI ALA C 354 UNP Q96RI1 GLU 364 ENGINEERED MUTATION SEQRES 1 A 233 GLY SER HIS MET GLU LEU THR PRO ASP GLN GLN THR LEU SEQRES 2 A 233 LEU HIS PHE ILE MET ASP SER TYR ASN LYS GLN ARG MET SEQRES 3 A 233 PRO GLN GLU ILE THR ASN LYS ILE LEU LYS GLU ALA PHE SEQRES 4 A 233 SER ALA GLU GLU ASN PHE LEU ILE LEU THR GLU MET ALA SEQRES 5 A 233 THR ASN HIS VAL GLN VAL LEU VAL GLU PHE THR LYS LYS SEQRES 6 A 233 LEU PRO GLY PHE GLN THR LEU ASP HIS GLU ASP GLN ILE SEQRES 7 A 233 ALA LEU LEU LYS GLY SER ALA VAL GLU ALA MET PHE LEU SEQRES 8 A 233 ARG SER ALA GLU ILE PHE ASN LYS LYS LEU PRO SER GLY SEQRES 9 A 233 HIS SER ASP LEU LEU GLU ALA ARG ILE ARG ASN SER GLY SEQRES 10 A 233 ILE SER ASP GLU TYR ILE THR PRO MET PHE SER PHE TYR SEQRES 11 A 233 LYS SER ILE GLY GLU LEU LYS MET THR GLN GLU GLU TYR SEQRES 12 A 233 ALA LEU LEU THR ALA ILE VAL ILE LEU SER PRO ASP ARG SEQRES 13 A 233 GLN TYR ILE LYS ASP ARG GLU ALA VAL GLU LYS LEU GLN SEQRES 14 A 233 GLU PRO LEU LEU ASP VAL LEU GLN LYS LEU CYS LYS ILE SEQRES 15 A 233 HIS GLN PRO GLU ASN PRO GLN HIS PHE ALA CYS LEU LEU SEQRES 16 A 233 GLY ARG LEU THR GLU LEU ARG THR PHE ASN HIS HIS HIS SEQRES 17 A 233 ALA GLU MET LEU MET SER TRP ARG VAL ASN ASP HIS LYS SEQRES 18 A 233 PHE THR PRO LEU LEU CYS GLU ILE TRP ASP VAL GLN SEQRES 1 B 14 LYS ASP HIS GLN LEU LEU ARG TYR LEU LEU ASP LYS ASP SEQRES 2 B 14 GLU SEQRES 1 C 233 GLY SER HIS MET GLU LEU THR PRO ASP GLN GLN THR LEU SEQRES 2 C 233 LEU HIS PHE ILE MET ASP SER TYR ASN LYS GLN ARG MET SEQRES 3 C 233 PRO GLN GLU ILE THR ASN LYS ILE LEU LYS GLU ALA PHE SEQRES 4 C 233 SER ALA GLU GLU ASN PHE LEU ILE LEU THR GLU MET ALA SEQRES 5 C 233 THR ASN HIS VAL GLN VAL LEU VAL GLU PHE THR LYS LYS SEQRES 6 C 233 LEU PRO GLY PHE GLN THR LEU ASP HIS GLU ASP GLN ILE SEQRES 7 C 233 ALA LEU LEU LYS GLY SER ALA VAL GLU ALA MET PHE LEU SEQRES 8 C 233 ARG SER ALA GLU ILE PHE ASN LYS LYS LEU PRO SER GLY SEQRES 9 C 233 HIS SER ASP LEU LEU GLU ALA ARG ILE ARG ASN SER GLY SEQRES 10 C 233 ILE SER ASP GLU TYR ILE THR PRO MET PHE SER PHE TYR SEQRES 11 C 233 LYS SER ILE GLY GLU LEU LYS MET THR GLN GLU GLU TYR SEQRES 12 C 233 ALA LEU LEU THR ALA ILE VAL ILE LEU SER PRO ASP ARG SEQRES 13 C 233 GLN TYR ILE LYS ASP ARG GLU ALA VAL GLU LYS LEU GLN SEQRES 14 C 233 GLU PRO LEU LEU ASP VAL LEU GLN LYS LEU CYS LYS ILE SEQRES 15 C 233 HIS GLN PRO GLU ASN PRO GLN HIS PHE ALA CYS LEU LEU SEQRES 16 C 233 GLY ARG LEU THR GLU LEU ARG THR PHE ASN HIS HIS HIS SEQRES 17 C 233 ALA GLU MET LEU MET SER TRP ARG VAL ASN ASP HIS LYS SEQRES 18 C 233 PHE THR PRO LEU LEU CYS GLU ILE TRP ASP VAL GLN SEQRES 1 D 14 LYS ASP HIS GLN LEU LEU ARG TYR LEU LEU ASP LYS ASP SEQRES 2 D 14 GLU HET OKI A 2 32 HET OKI C 1 32 HETNAM OKI (2S)-2-[2-(4-CHLOROPHENYL)-1H-BENZIMIDAZOL-1-YL]-N,2- HETNAM 2 OKI DICYCLOHEXYLETHANAMIDE FORMUL 5 OKI 2(C27 H32 CL N3 O) FORMUL 7 HOH *40(H2 O) HELIX 1 1 THR A 250 ASN A 265 1 16 HELIX 2 2 MET A 269 GLU A 280 1 12 HELIX 3 3 SER A 283 LYS A 308 1 26 HELIX 4 4 GLY A 311 LEU A 315 5 5 HELIX 5 5 ASP A 316 ASN A 341 1 26 HELIX 6 6 GLY A 347 ASN A 358 1 12 HELIX 7 7 SER A 362 GLU A 378 1 17 HELIX 8 8 THR A 382 LEU A 395 1 14 HELIX 9 9 ASP A 404 GLN A 427 1 24 HELIX 10 10 GLN A 432 THR A 446 1 15 HELIX 11 11 HIS A 450 SER A 457 1 8 HELIX 12 12 THR A 466 TRP A 473 1 8 HELIX 13 13 HIS B 746 LEU B 753 1 8 HELIX 14 14 THR C 250 ASN C 265 1 16 HELIX 15 15 MET C 269 GLU C 280 1 12 HELIX 16 16 SER C 283 LYS C 308 1 26 HELIX 17 17 GLY C 311 LEU C 315 5 5 HELIX 18 18 ASP C 316 LYS C 342 1 27 HELIX 19 19 GLY C 347 ASN C 358 1 12 HELIX 20 20 SER C 362 LEU C 379 1 18 HELIX 21 21 THR C 382 LEU C 395 1 14 HELIX 22 22 ASP C 404 GLN C 427 1 24 HELIX 23 23 GLN C 432 MET C 456 1 25 HELIX 24 24 THR C 466 ASP C 474 1 9 HELIX 25 25 HIS D 746 ASP D 754 1 9 SITE 1 AC1 11 ILE A 273 ILE A 277 MET A 294 HIS A 298 SITE 2 AC1 11 MET A 332 SER A 336 ILE A 356 SER A 359 SITE 3 AC1 11 MET A 369 TYR A 373 MET A 454 SITE 1 AC2 9 ILE C 273 ASN C 287 MET C 294 HIS C 298 SITE 2 AC2 9 MET C 332 ARG C 335 SER C 336 ILE C 339 SITE 3 AC2 9 TYR C 373 CRYST1 72.215 84.528 190.240 90.00 90.00 90.00 C 2 2 21 16 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.013848 0.000000 0.000000 0.00000 SCALE2 0.000000 0.011830 0.000000 0.00000 SCALE3 0.000000 0.000000 0.005257 0.00000